Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has announced a strategic partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the Lunit Research Program, granting SITC members access to Lunit SCOPE® IO, a powerful AI tool for quantitative immune phenotyping and tumor microenvironment (TME) analysis using H&E whole slide images (WSIs).
About SITC:
SITC is the premier, member-driven organization dedicated to advancing the field of cancer immunotherapy. Its mission is to improve cancer patient outcomes by promoting the science and clinical application of immunotherapy.
Program Overview:
Through the Lunit Research Program, SITC members, including academic and non-profit researchers, will gain access to Lunit SCOPE IO at no cost. This initiative aims to support advanced research in immunotherapy by enabling researchers to perform detailed analyses of histologic features from H&E whole slide images.
Key features of the program include:
- Cell Identification: Analyzing Tumor-Infiltrating Lymphocytes (TILs), macrophages, endothelial cells, and more.
- Tissue Segmentation and Quantitative Immune Phenotyping: Classifying TME into inflamed, excluded, and desert phenotypes.
- Insights for Biomarker Discovery and Immunotherapy Research: Advancing cancer immunotherapy through deep data insights.
Lunit SCOPE IO:
Lunit SCOPE IO is an AI-powered solution designed to bridge the gap between pathology and precision oncology. It quantifies histology from H&E whole slide images, providing insights into the immune landscape of tumors and enabling the identification of biomarkers predictive of immunotherapy responses.
The solution provides comprehensive capabilities to advance cancer immunotherapy research:
- Quantitative Immune Phenotyping: Classifies the TME into distinct categories for more targeted immunotherapy strategies.
- TIL Analysis: Identifies and quantifies Tumor-Infiltrating Lymphocytes, a key indicator of immune response.
- Comprehensive TME Profiling: Analyzes stromal and immune components, including fibroblasts, macrophages, and endothelial cells.
- Support for Biomarker Discovery: Helps uncover new biomarkers and evaluate correlations with therapeutic outcomes.
Strategic Collaboration for Advancing Cancer Research:
This partnership aligns with Lunit’s mission to integrate AI-powered image analysis into both routine cancer diagnostics and clinical research. By collaborating with SITC, the global leader in immunotherapy research, Lunit aims to support the ongoing advancement of cancer immunotherapy through the use of AI-driven insights in collaboration with top researchers in the field.
